


Supplementary data: External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer

David Tiberi, MD¹; George Rodrigues, MD²; Tom Pickles, MD³; Jim Morris, MD³; Juanita Crook, MD⁴; Andre-Guy Martin, MD⁵; Fabio Cury, MD⁶; Charles Catton, MD⁷; Himu Lukka, MD⁸; Andrew Warner, MD⁹; Daniel Taussky, MD¹

¹Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Hôpital Notre-Dame, Montreal, QC; ²Department of Oncology, London Health Sciences Centre; Schulich School of Medicine & Dentistry, Western University, London, ON; ³Department of Radiation Oncology, BC Cancer Agency, Vancouver Centre, University of British Columbia, Vancouver, BC; ⁴Department of Radiation Oncology, BC Cancer Agency, Kelowna, BC; ⁵Department of Radiation Oncology, Centre Hospitalier Universitaire de Québec-L'Hôtel-Dieu de Québec, Quebec City, QC; ⁶Department of Oncology, Division of Radiation Oncology, McGill University Health Centre, Montreal, QC; ⁷Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON; ⁸Department of Radiation Oncology, Juravinski Cancer Centre, Hamilton, ON; ⁹Department of Radiation Oncology, London Health Sciences Centre, London, ON; Canada

Published online April 11, 2017



Supplementary Fig. 1. ProCaRS nomograms predicting five-year ASTRO II Phoenix biochemical failure-free survival for (A) LDR-brachytherapy only (n=4208); and (B) EBRT only (reproduced with permission from Cureus). ADT: androgen-deprivation therapy; BED: biologically effective dose; BFFS: biochemical failure-free survival; PSA: prostate-specific antigen.

Supplementary Table 1. Summary of actuarial estimates for biochemical-failure-free survival and overall survival for each risk stratification variable for the CHUM database (n=2266)

Group	Median (Years)	3Y (%)	4Y (%)	5Y (%)	10Y (%)
Biochemical-failure-free survival					
All patients	NR	97.4	95.2	92.9	72.0
CAPRA-3					
Low	NR	98.7	97.9	96.6	82.7
Intermediate	NR	96.6	94.7	91.7	70.0
High	NR	95.3	87.9	85.2	62.3
ProCaRS, n (%)					
Low	NR	98.3	97.3	96.2	82.1
Low-intermediate	NR	97.1	94.8	91.7	65.5
High-intermediate	NR	94.7	90.2	86.4	70.2
High	NR	96.9	94.3	92.9	74.6
Very high	9.34	95.1	87.1	82.4	45.8
GUROC, n (%)					
Low	NR	98.3	97.3	96.2	82.1
Intermediate	NR	96.8	94.2	91.0	68.3
High	NR	96.2	91.5	88.8	65.2
NCCN ^{1,2}					
Low	NR	98.4	97.5	96.2	81.8
Intermediate	NR	96.7	94.2	91.1	68.3
High	NR	96.0	92.7	90.0	65.2
Overall survival					
All patients	NR	97.9	96.2	94.7	80.6
CAPRA-3					
Low	NR	99.0	98.3	98.1	94.4
Intermediate	NR	97.4	94.8	93.5	77.8
High	NR	96.4	94.3	89.2	72.6
ProCaRS, n (%)					
Low	NR	99.1	98.4	97.9	96.5
Low-intermediate	NR	97.4	95.0	93.4	72.1
High-intermediate	NR	95.0	92.2	90.2	85.6
High	NR	98.3	97.1	95.6	78.6
Very high	11.84	96.9	91.3	85.1	69.5
GUROC, n (%)					
Low	NR	99.1	98.4	97.9	96.5
Intermediate	NR	96.9	94.5	92.9	75.4
High	NR	97.7	94.7	91.3	74.8
NCCN ^{1,2}					
Low	NR	99.3	98.7	98.1	96.7
Intermediate	NR	96.8	94.4	92.8	75.6
High	NR	97.6	95.3	91.8	77.2

¹Very low and low combined due to low number of patients with T1a disease; ²very high not reported for CHUM database (n=8). CAPRA: Cancer of the Prostate Risk Assessment; ProCaRS: Prostate Cancer Risk Stratification; GUROC: Genitourinary Radiation Oncologists of Canada; NCCN: National Comprehensive Cancer Network; NR: not reached.